In early axial spondyloarthritis (ax SpA), joint damage cannot be seen on an x-ray but could be detected with an MRI scan. This stage is referred to as non-radiographic axial spondyloarthritis (nr-ax SpA) meaning ax SpA that cannot be seen on an x-ray.

Chronic back pain is one symptom of nr-ax SpA

RE-EMBARK

Consider participating in the RE-EMBARK Study

Take the first step.

For more information or to see if you qualify for this study, please contact:

Are you living with chronic low back pain?

B1801381: A Clinical Study for Non-Radiographic Axial Spondyloarthritis

RE-EMBARK

Models in photos are for illustrative purposes only

Do you suffer from chronic pain and stiffness in the lower back, hip joints, and buttocks during the waking hours and after periods of inactivity? If your nr-ax SpA symptoms persist despite current treatments, you may want to consider participating in a clinical research study with an investigational study medication.



By participating in the RE-EMBARK study, you will be taking a more active role in your own health care. Your participation may help doctors confirm the treatment duration with the study drug in patients with nr-ax SpA. The duration of the study is approximately 18 months.



Nearly **60%** of the cases of early stage nr-ax SpA are in **women**.

You may be eligible to participate in this clinical study if you:

- Are 18 to 49 years of age;
- Currently take an anti-inflammatory drug for nr-ax SpA and continue to have back pain;
- Have had nr-ax SpA symptoms for at least 3 months and less than 5 years;
- Are willing to follow a study treatment plan, routinely scheduled study visits and other study tests and procedures.

Not all eligibility requirements for this study are listed here. Ask your doctor to find out more about this research study to see if you might qualify for participation.

Study FAQs

Following are some frequently asked questions about clinical trials.

How do I know if I qualify for the RE-EMBARK clinical study?

If you are 18 to 49 years old and have had symptoms of nr-ax SpA for at least 3 months and less than 5 years, you may be eligible to participate. Both men and women can participate. Your physician or study doctor will be able to determine your eligibility.

How much does it cost to participate in the clinical study?

It does not cost anything to enroll in the RE-EMBARK study. For study participants, all investigational medication, study related procedures and study doctor's visits will be provided at no cost to you for the duration of the study. Qualified participants may receive reimbursement for study-related expenses.

How long will I be enrolled in this study?

If you are eligible and decide to enroll in the RE-EMBARK study, your participation will last approximately 64 weeks (a little over a year). Patients may stop participation in the trial at any time. Participation includes initial treatment and a period of study treatment withdrawal.

Why is the investigational drug being studied for this condition?

The investigational drug in this study is being investigated to see if it can be used for people with nr-ax SpA who have had an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs).

How is the investigational drug administered?

The investigational study drug is administered as a subcutaneous injection (under the skin) once a week.

What can I expect if I participate in a clinical study?

An informed consent document will be given to you that includes information about the clinical study, as well as potential benefits and possible risks associated with the research.

An independent ethics group will review the study periodically. You will also be monitored by the research team to assess your health and well-being. You are free to leave the clinical study at any time.

You should carefully consider and talk with your doctors and family about both the potential benefits and risks of participation before enrolling in a clinical study.

Nr-ax SpA is typically found in people **under the age of 45, many in their 20's and 30's**, and in the most active period of their lives.